Carmela Di Dio

Carmela Di Dio

Auto-generated profile, based on publicly available information

Carmela Di Dio

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
CDCarmela Di Dio
Carmela Di Dio
GCGiuditta Chiloiro
Giuditta Chiloiro
DCDavide Cusumano
Davide Cusumano
FCFrancesco Catucci
Francesco Catucci
LBLuca Boldrini
Luca Boldrini
Maria Antonietta GambacortaMaria Antonietta Gambacorta
Maria Antonietta Gambacorta
Introduction: The aim of this study was to create a radiomic model able to calculate the probability of 5-year disease-free survival (5yDFS) when oxaliplatin (OXA) is or not administered in patients with locally advanced rectal cancer (LARC) and treated with neoadjuvant chemoradiotherapy (nCRT), allowing physicians to choose the best chemotherapy (CT) regimen.Methods: LARC patients with cT3–4 cN0 or cT1–4 cN1–2 were treated according to an nCRT protocol that included concomitant CT schedules with or without OXA and radiotherapy dose of 55 Gy in 25 fractions. Radiomic analysis was performed on the T2-weighted (T2-w) MR images acquired during the initial tumor staging. Statistical analysis was performed separately for the cohort of patients treated with and without OXA. The ability of every single radiomic feature in predicting 5yDFS as a univariate analysis was assessed using the Wilcoxon–Mann–Whitney (WMW) test or t-test. Two logistic models (one for each cohort) were calculated, and their performance was assessed using the area under the receiver operating characteristic (ROC) curve (AUC).Results: A total of 176 image features belonging to four families (morphological, statistical, textural, and fractal) were calculated for each patient. At the univariate analysis, the only feature showing significance in predicting 5yDFS was the maximum fractal dimension of the subpopulation identified considering 30% and 50% as threshold levels (maxFD30–50). Once the models were developed using this feature, an AUC of 0.67 (0.57–0.77) and 0.75 (0.56–0.95) was obtained for patients treated with and without OXA, respectively. A maxFD30–50 >1.6 was correlated to a higher 5yDFS probability in patients treated with OXA.Conclusion: This study suggests that radiomic analysis of MR T2-w images can be used to define the optimal concomitant CT regimen for stage III LARC cancer patients. In particular, by providing an indication of the gross tumor volume (GTV) spatial heterogeneity at initial staging, maxFD30–50 seems to be able to predict the probability of 5yDFS. New studies including a larger cohort of patients and external validation sets are recommended to verify the results of this hypothesis-generating study.

13 October 2016 in Biomarkers in Medicine
Verified
Journal Article
Closed access
Armando OrlandiArmando Orlandi
Armando Orlandi
CDCarmela Di Dio
Carmela Di Dio
MCMaria Alessandra Calegari
Maria Alessandra Calegari
CBCarlo Barone
Carlo Barone
Everolimus and exemestane represent a standard treatment for metastatic hormone receptor-positive/HER2-negative advanced breast cancer resistant to aromatase inhibitors. CA 15–3 serum levels detect soluble forms of MUC-1, a transmembrane oncoprotein aberrantly overexpressed in breast cancers. In clinical practice, CA 15–3 may be used to indicate treatment failure in the absence of readily measurable disease during cytotoxic therapy. In the targeted therapy era, it is important to note that the C-terminal subunit of MUC-1 interacts with PI3K/AKT pathway, inducting cell growth. Vice versa, the block of this pathway may influence MUC-1 expression and CA 15–3 serum levels. In this report, we emphasize the equivocal role of CA 15–3 serum levels in monitoring treatment with everolimus, suggesting a potential and intriguing role of a CA 15–3 increase as paradox predictive biomarker of response to everolimus.

1 February 2017 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Closed access
PDF file
SRSabrina Rossi
Sabrina Rossi
TCTeresa Congedo
Teresa Congedo
RRRiccardo Ricci
Riccardo Ricci
MMMaurizio Martini
Maurizio Martini
VNVincenzo Di Noia
Vincenzo Di Noia
ACAlessandra Cassano
Alessandra Cassano
Oesophageal gastrointestinal stromal tumors (GISTs) are rare neoplasms (about 2% of all GISTs); radical surgery is the standard treatment of all GISTs but in case of locally advanced and unresectable disease no clear treatment guide lines are available. Studies including neoadjuvant imatinib mesylate (IM) are relatively recent, includes small sample size of heterogeneous patients and do not report a standardized duration of neoadjuvant treatment. The main question still remains whether surgery after neoadjuvant IM gives a survival benefit in locally advanced disease. A 46-year-old man with locally advanced unresectable oesophageal GIST harboring KIT exon 11 mutation was treated in our institution for 12 months with neoadjuvant IM; a reduction of 83% of tumor volume was obtained in 9-month of neoadjuvant IM, but in the last 3 months no further response was seen. After neoadjuvant therapy, patient underwent radical surgery and adjuvant IM, which is still ongoing. Since no definitive data are available about survival benefit of surgery after neoadjuvant IM in locally advanced GISTs, a careful balance between morbidity and mortality derived from surgery should be considered and more studies are needed to better define the utility and the optimal duration of neoadjuvant treatment.